InsiderTrades.com logo
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>

OLY Insider Trading

Insider Ownership Percentage: 34.54%
Insider Buying (Last 12 Months): C$260,200.65
Insider Selling (Last 12 Months): C$23,923.00

Olympia Financial Group Insider Trading History Chart

This chart shows the insider buying and selling history at Olympia Financial Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Olympia Financial Group Share Price & Price History

Current Price: C$110.59
Price Change: ▼ Price Decrease of -3.39 (-2.97%)
As of 04/19/2024 05:22 PM ET

This chart shows the closing price history over time for OLY up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>

Olympia Financial Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Rick SkaugeDirectorBuy35C$106.50C$3,727.50
3/8/2024Rick SkaugeDirectorBuy35C$106.25C$3,718.75
1/15/2024Anthony LanzlDirectorSell200C$94.12C$18,823.00
12/4/2023Rick SkaugeDirectorBuy50C$92.00C$4,600.00
11/30/2023Rick SkaugeDirectorBuy555C$90.00C$49,950.00
11/24/2023Antony BalasubramanianDirectorBuy100C$90.99C$9,099.00750
11/21/2023Anthony LanzlDirectorBuy800C$88.50C$70,800.00
11/17/2023Anthony LanzlDirectorBuy1,000C$87.25C$87,250.00
11/14/2023Gerardus Adrianus JanssenDirectorBuy300C$86.00C$25,800.00
11/6/2023Philip Alan Du HeaumeDirectorSell60C$85.00C$5,100.00602
10/25/2023Philip Alan Du HeaumeDirectorBuy60C$87.59C$5,255.40662
3/1/2023Rick SkaugeDirectorBuy50C$73.50C$3,675.00
1/3/2023Rick SkaugeDirectorBuy60C$69.01C$4,140.6023,372
12/2/2022Rick SkaugeDirectorBuy40C$69.90C$2,796.0023,312
10/21/2022Anthony LanzlDirectorSell200C$61.00C$12,200.004,894
10/17/2022Rick SkaugeDirectorBuy100C$62.33C$6,233.0023,257
9/30/2022Rick SkaugeDirectorBuy22C$61.95C$1,362.9023,157
9/2/2022Rick SkaugeDirectorBuy149C$62.00C$9,238.0023,135
7/20/2022Rick SkaugeDirectorBuy80C$61.00C$4,880.0022,986
7/12/2022Philip Alan Du HeaumeDirectorBuy22C$64.00C$1,408.00527
7/6/2022Gerardus Adrianus JanssenDirectorBuy300C$65.37C$19,611.005,500
6/3/2022Rick SkaugeDirectorBuy100C$59.00C$5,900.0022,906
5/20/2022Gerardus Adrianus JanssenDirectorBuy200C$58.50C$11,700.005,200
5/18/2022Rick SkaugeDirectorBuy300C$57.91C$17,373.0022,556
8/31/2021Rick SkaugeDirectorBuy25C$48.60C$1,215.0022,231
7/19/2021Rick SkaugeDirectorBuy45C$47.40C$2,133.0022,206
7/14/2021Gerhard Stephanus BarnardSenior OfficerBuy250C$46.73C$11,682.501,100
7/9/2021Rick SkaugeDirectorBuy54C$46.00C$2,484.0022,161
5/21/2021Rick SkaugeDirectorBuy65C$51.95C$3,376.7522,107
See Full Table
Strange new buyer driving up gold
From Stansberry Research   |   Ad
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
But there's a much better move you can make to get in front of these big moves today.

SEC Filings (Institutional Ownership Changes) for Olympia Financial Group (TSE:OLY)

0.71% of Olympia Financial Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Olympia Financial Group logo
Olympia Financial Group Inc., through its subsidiary, Olympia Trust Company, operates as a non-deposit taking trust company in Canada. The company operates through Investment Account Services, Currency and Global Payments, Private Health Services Plan, Exempt Edge, and Corporate and Shareholder Services divisions. The Investment Account Services division specializes in self-directed registered plans administration. The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies. The Private Health Services Plan division markets, sells, and administers health and dental benefits to business owners. The Exempt Edge division focuses on the provision of information technology to exempt market dealers, registrants, and issuers. The Corporate and Shareholder Services division provides transfer agency and corporate trust services to public and private issuers. The company was incorporated in 1994 and is headquartered in Calgary, Canada.
Read More on Olympia Financial Group

Today's Range

Now: C$110.59
Low: C$110.59
High: C$112.29

50 Day Range

MA: C$109.36
Low: C$101.51
High: C$120.75

52 Week Range

Now: C$110.59
Low: C$64.80
High: C$122.35

Volume

215 shs

Average Volume

1,855 shs

Market Capitalization

C$266.52 million

P/E Ratio

11.67

Dividend Yield

6.87%

Beta

0.37

Who are the company insiders with the largest holdings of Olympia Financial Group?

Olympia Financial Group's top insider shareholders include:
  1. Rick Skauge (Director)
  2. Gerardus Adrianus Janssen (Director)
  3. Anthony Lanzl (Director)
  4. Antony Balasubramanian (Director)
  5. Philip Alan Du Heaume (Director)
Learn More about top insider investors at Olympia Financial Group.
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>